Asad Haider
Stock Analyst at Goldman Sachs
(2.38)
# 2,440
Out of 4,868 analysts
6
Total ratings
100%
Success rate
8.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Initiates: Neutral | $110 | $104.40 | +5.36% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $150.73 | +14.11% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $785.03 | +13.12% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $185.49 | +4.59% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $46.84 | +17.42% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $23.88 | +4.69% | 1 | Apr 8, 2025 |
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $104.40
Upside: +5.36%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $150.73
Upside: +14.11%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $785.03
Upside: +13.12%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $185.49
Upside: +4.59%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $46.84
Upside: +17.42%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $23.88
Upside: +4.69%